Chemobrain: why does your brain feel like it's working slower after chemotherapy?

Many patients experience changes in their thinking that they did not experience before, during or after cancer treatment. They describe them as “foggy brain,” slower processing of information, forgetfulness, or difficulty concentrating. In medicine, this phenomenon is called chemobrain or chemofog—cognitive impairments associated with cancer treatment.

Although the name suggests that it is exclusively chemotherapy, we now know that the situation is more complex. Similar problems can also occur in patients receiving hormone therapy, targeted therapy, or immunotherapy, and even before treatment begins.

How does chemobrain manifest itself and what does the science say?

Patients most often describe memory problems, decreased concentration, a feeling of mental slowness, and problems with multitasking and word finding. The problems are usually mild to moderate, but they can significantly affect the quality of life, especially for people who do mentally demanding jobs.

One of the frequently cited studies published in the journal Cancer (Wefel et al.) showed that a significant proportion of patients had measurable cognitive changes already during chemotherapy, but also before it began, which suggests that the cause is not solely the therapy.

A large prospective study published in the Journal of Clinical Oncology (Janelsins et al., 2017) followed women with breast cancer and showed that some patients had persistent cognitive impairment for up to several years after the end of treatment, although most gradually recovered.

Also, research using functional magnetic resonance imaging (fMRI) showed changes in brain activity and connectivity in certain regions, which further confirms that this is a real biological phenomenon, and not a subjective impression.

Why does it occur and how long does it last?

The exact mechanism is not fully understood, but it is most likely a combination of several factors: the direct effect of therapy on the brain, inflammatory processes, hormonal changes, fatigue, sleep disorders, anxiety and the impact of the cancer itself. It is estimated that symptoms of chemobrain occur in 20–70% of patients, depending on the type of treatment and the method of measuring cognitive functions. In other words, it is a much more common phenomenon than previously thought.

In most patients, the symptoms are temporary and gradually resolve after the end of treatment, most often within a few months. However, in a small number of patients, the symptoms can last longer.

Example from our practice: A patient in her early fifties, treated for breast cancer, presented a few months after the end of chemotherapy with a feeling of “mental slowness”. She described that it took her longer to complete everyday tasks, that she forgot appointments and that she had difficulty concentrating when reading. Before the illness, she had done administrative work without difficulty, but after the treatment she felt insecure in her own abilities. It was important for her to hear that this was a well-known and common phenomenon, and not a permanent impairment or “loss of ability.” With simple organizational strategies, a gradual return to mental activities, and normalizing sleep, the symptoms significantly decreased within a few months.

What can we do?

Although there is no specific cure, there are strategies that can help: structuring your daily routine (notes, reminders), mental activity, regular physical activity, quality sleep, and stress management. It is also important to talk to your doctor to rule out other potential causes of the problems.

In practice, this often means very simple but effective adjustments. For example, writing down your tasks in your phone or planner can significantly reduce the stress of forgetting, while setting reminders helps with daily organization. Instead of trying to do multiple tasks at once, it is more useful to focus on one activity and do it in shorter blocks of time with breaks.

For problems with concentration, working in a quiet environment without distractions, and turning off unnecessary notifications on your phone, helps. Some patients report that they also benefit from “mental training” such as reading, solving crossword puzzles or learning new, simple skills.

Physical activity does not have to be intense – even a regular walk can have a positive effect on cognitive function and a sense of energy. It is equally important to take care of the quality of sleep, as chronic fatigue further worsens symptoms.

It is important to emphasize that improvement most often does not occur overnight, but gradually, with patience and adjustment of daily habits. If, despite these measures, the symptoms persist or significantly affect daily functioning, it is important to see a doctor again. In this case, it is necessary to consider whether there are additional factors that may contribute to the disorders, such as anemia, thyroid disorders, side effects of therapy, depression or chronic fatigue. Additional treatment, including neuropsychological testing, may be useful for some patients, which helps to objectify the symptoms and direct further steps. In certain situations, structured cognitive rehabilitation is also recommended, under the guidance of a specialist, which can help improve attention, memory and executive functions through targeted exercises. The most important thing to emphasize is that in such situations the patient should not be left alone with the problem — although there is no "quick solution", there are ways to alleviate complaints and gradually improve functionality.

An important message to end with

Chemobrain is a real and recognized problem that can accompany cancer treatment. Although it is usually not permanent, it can be frustrating and affect daily life. It is important for patients to know that they are not alone and that these changes do not mean the loss of their abilities, but rather a temporary condition that many people go through.

References

1. Wefel, J.S., Lenzi, R., Theriault, R.L., Davis, R.N. and Meyers, C.A. (2004), The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma. Cancer, 100: 2292-2299. https://doi.org/10.1002/cncr.20272

2. Janelsins MC, Heckler CE, Peppone LJ, Ahles TA, Mohile SG, Mustian KM, Palesh O, O'Mara AM, Minasian LM, Williams AM, Magnuson A, Geer J, Dakhil SR, Hopkins JO, Morrow GR. Longitudinal Trajectory and Characterization of Cancer-Related Cognitive Impairment in a Nationwide Cohort Study. J Clin Oncol. 2018 Sep 21;36(32):JCO2018786624. doi: 10.1200/JCO.2018.78.6624. Epub ahead of print. PMID: 30240328; PMCID: PMC6225503.

Need more information about this topic? Contact us.